Kamada Ltd
KMDA
View Detailed Chart
7.070USD
-0.020-0.28%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
407.81MMarket Cap
20.11P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.28%
5 Days
-2.88%
1 Month
+3.97%
6 Months
-8.30%
Year to Date
+16.09%
1 Year
+19.53%
View Detailed Chart
TradingKey Stock Score of Kamada Ltd
Currency: USD Updated: 2025-12-26Key Insights
Kamada Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 55/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.00.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Kamada Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Buy
Current Rating
13.000
Target Price
+93.16%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Kamada Ltd Highlights
StrengthsRisks
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 24.44% year-on-year.
Fairly Valued
The company’s latest PE is 20.11, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 26.81M shares, decreasing 10.38% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 256.22K shares of this stock.
Kamada Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Kamada Ltd Info
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Ticker SymbolKMDA
CompanyKamada Ltd
CEOLondon (Amir)
Websitehttps://www.kamada.com/
FAQs
What is the current price of Kamada Ltd (KMDA)?
The current price of Kamada Ltd (KMDA) is 7.070.
What is the symbol of Kamada Ltd?
The ticker symbol of Kamada Ltd is KMDA.
What is the 52-week high of Kamada Ltd?
The 52-week high of Kamada Ltd is 9.155.
What is the 52-week low of Kamada Ltd?
The 52-week low of Kamada Ltd is 5.540.
What is the market capitalization of Kamada Ltd?
The market capitalization of Kamada Ltd is 407.81M.
What is the net income of Kamada Ltd?
The net income of Kamada Ltd is 14.46M.
Is Kamada Ltd (KMDA) currently rated as Buy, Hold, or Sell?
According to analysts, Kamada Ltd (KMDA) has an overall rating of Buy, with a price target of 13.000.
What is the Earnings Per Share (EPS TTM) of Kamada Ltd (KMDA)?
The Earnings Per Share (EPS TTM) of Kamada Ltd (KMDA) is 0.352.
Related Instruments
+0.05%
-0.07%
+0.08%
+0.49%
+0.23%
+0.38%
-0.31%
-0.30%
-0.77%
+0.30%
+0.23%
-0.02%
-0.07%
+0.24%
+0.26%
+0.30%
+0.16%
0.00%
+0.58%
-0.02%Popular Symbols
